文献速递衰弱、肌少症与跌倒多重用药老年综合评估

威尔士老年衰弱人群抗胆碱能负担的横断面分析

The extent of anticholinergic burden across an older Welsh population living with frailty: cross-sectional analysis of general practice records.
PubMed 文献 · Age Ageing · 2023-01-01

该研究基于威尔士初级保健数据库,纳入2018年首次全科就诊的≥65岁患者529,095例,用电子衰弱指数识别衰弱、用抗胆碱能认知负担(ACB)量表评估负担。结果显示,接受任何处方的患者中47.4%被处方至少一种抗胆碱能药;校正回归分析中,衰弱程度越高,ACB-Sum>3的比值比越高(重度衰弱 adj OR 1.208,95%CI 1.203-1.213)。作者建议对衰弱进展的老年人进行药物审查以减少抗胆碱能药蓄积。

要点

  • 接受任何处方的老年患者中47.4%被处方至少一种抗胆碱能药。
  • 衰弱程度越高,ACB-Sum>3的比值比越高,重度衰弱 adj OR 1.208(95%CI 1.203-1.213)。
  • 对衰弱进展的老年人应考虑药物审查,以防抗胆碱能药蓄积。

核心结论

  • 威尔士老年人群中抗胆碱能药处方普遍,衰弱程度越高者抗胆碱能负担越重。

研究设计与样本

  • 威尔士初级保健数据(Secure Anonymised Information Linkage databank)的横断面分析。
  • 用电子衰弱指数识别衰弱,用抗胆碱能认知负担(ACB)量表评估抗胆碱能负担,行描述性分析与logistic回归。

主要发现

  • 接受任何处方药的患者中,47.4%被处方至少一种抗胆碱能药。
  • 校正回归分析显示,与健康(fit)者相比,衰弱程度增加者ACB-Sum>3的比值比更高。
  • 轻度衰弱 adj OR 1.062(95%CI 1.061-1.064),中度衰弱 adj OR 1.134(95%CI 1.131-1.136),重度衰弱 adj OR 1.208(95%CI 1.203-1.213)。

关键数值与推荐

  • ACB-Sum>3作为累积抗胆碱能负担的判定指标。
  • 衰弱按电子衰弱指数分为轻度、中度、重度,与健康(fit)者比较。

临床怎么用

  • 对衰弱进展的老年人考虑药物审查,避免抗胆碱能药过度蓄积。
  • 关注衰弱老年人功能与认知下降风险,权衡抗胆碱能药处方。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anticholinergic medicines are associated with adverse outcomes for older people. However, little is known about their use in frailty. The objectives were to (i) investigate the prevalence of anticholinergic prescribing for older patients, and (ii) examine anticholinergic burden according to frailty status. METHODS: Cross-sectional analysis of Welsh primary care data from the Secure Anonymised Information Linkage databank including patients aged ≥65 at their first GP consultation between 1 January and 31 December 2018. Frailty was identified using the electronic Frailty Index and anticholinergic burden using the Anticholinergic Cognitive Burden (ACB) scale. Descriptive analysis and logistic regression were conducted to (i) describe the type and frequency of anticholinergics prescribed; and (ii) to estimate the association between frailty and cumulative ACB score (ACB-Sum). RESULTS: In this study of 529,095 patients, 47.4% of patients receiving any prescription medications were prescribed at least one anticholinergic medicine. Adjusted regression analysis showed that patients with increasing frailty had higher odds of having an ACB-Sum of >3 compared with patients who were fit (mild frailty, adj OR 1.062 (95%CI 1.061-1.064), moderate frailty, adj OR 1.134 (95%CI 1.131-1.136), severe frailty, adj OR 1.208 (95%CI 1.203-1.213)). CONCLUSIONS: Anticholinergic prescribing was high in this older population. Older people with advancing frailty are exposed to the highest anticholinergic burden despite being the most vulnerable to the associated adverse effects. Older people with advancing frailty should be considered for medicines review to prevent overaccumulation of anticholinergic medications, given the risks of functional and cognitive decline that frailty presents.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Cheong VL, Mehdizadeh D, Todd OM, et al. The extent of anticholinergic burden across an older Welsh population living with frailty: cross-sectional analysis of general practice records. Age Ageing. 2023. PMID: 37505992. doi:10.1093/ageing/afad136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。